|
Re: AACR
|
2
|
Zenith Epigenetics
|
Apr 01, 2019 02:39PM
|
|
Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference
|
3
|
Resverlogix Corp.
|
Apr 01, 2019 01:29PM
|
|
Re: Playing with Number of patient years and RRR%
|
3
|
Resverlogix Corp.
|
Apr 01, 2019 11:24AM
|
|
Re: RESVERLOGIX ANNOUNCES. $15.1 MILLION OF PRIVATE PLACEMENTS
|
4
|
Resverlogix Corp.
|
Apr 01, 2019 11:12AM
|
|
Resverlogix Announces $15.1 Million of Private Placements
|
3
|
Resverlogix Corp.
|
Apr 01, 2019 11:10AM
|
|
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference
|
6
|
Resverlogix Corp.
|
Apr 01, 2019 11:08AM
|
|
Re: Recent changes
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 31, 2019 06:17PM
|
|
Re: Recent changes
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 31, 2019 06:12PM
|
|
Re: What else can RVX treat that we don’t know about yet?
|
7
|
Resverlogix Corp.
|
Mar 31, 2019 04:01PM
|
|
Re: What else can RVX treat that we don’t know about yet?
|
5
|
Resverlogix Corp.
|
Mar 31, 2019 08:35AM
|
|
Recent changes
|
2
|
BIOASIS TECHNOLOGIES INC
|
Mar 31, 2019 08:19AM
|
|
Re: AACR
|
5
|
Zenith Epigenetics
|
Mar 31, 2019 08:05AM
|
|
Re: What else can RVX treat that we don’t know about yet?
|
2
|
Resverlogix Corp.
|
Mar 31, 2019 07:40AM
|
|
Re: Any evidence of success in 2 subgroups
|
3
|
Resverlogix Corp.
|
Mar 30, 2019 10:18PM
|
|
Re: What would a success NR look like?
|
5
|
Resverlogix Corp.
|
Mar 30, 2019 04:27PM
|
|
Re: What would a success NR look like?
|
5
|
Resverlogix Corp.
|
Mar 30, 2019 03:20PM
|
|
Re: No mention of efficacy again...
|
7
|
Resverlogix Corp.
|
Mar 30, 2019 08:56AM
|
|
Re: AD/PD 2019 March 26-31, 2019
|
4
|
Resverlogix Corp.
|
Mar 30, 2019 08:39AM
|
|
Re: A vs V
|
2
|
Resverlogix Corp.
|
Mar 29, 2019 09:27PM
|
|
Re: American Association for Cancer Research 2019
|
3
|
Zenith Epigenetics
|
Mar 29, 2019 09:13PM
|
